Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine

BACKGROUND: Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status. Current mandatory mutation testing for patient selection is limited to the K-Ras ‘hotspot’ codons 12 and 13. METHODS: Colorectal tumours (n=106) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, G, Bounds, R, Wolf, H, Steele, R J C, Carey, F A, Wolf, C R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837563/
https://www.ncbi.nlm.nih.gov/pubmed/20147967
http://dx.doi.org/10.1038/sj.bjc.6605534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837563/
https://www.ncbi.nlm.nih.gov/pubmed/20147967
http://dx.doi.org/10.1038/sj.bjc.6605534

Ejemplares similares